Silymarin improved 6-OHDA-induced motor impairment in hemi-parkisonian rats: Behavioral and molecular study

DARU, Journal of Pharmaceutical Sciences

Volumn 22, Issue 1, 2014, Pages

  Haddadi, Rasool ^a   Nayebi, Alireza Mohajjel ^a,b   Farajniya, Safar ^b   Brooshghalan, Shahla Eyvari ^b   Sharifi, Hamdolah ^c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

6 OHDA; Catalepsy; IL 1 ; MDA; Rat; Rotarod; Silymarin

Indexed keywords

INTERLEUKIN 1BETA; MALONALDEHYDE; OXIDOPAMINE; SILYMARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN LEVEL; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; LIPID BRAIN LEVEL; MALE; MOTOR COORDINATION; MOTOR DYSFUNCTION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; RAT; ROTAROD TEST; SUBSTANTIA NIGRA PARS COMPACTA; SUPERNATANT;

EID: 84899900564     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/2008-2231-22-38     Document Type: Article

References (42)

1. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. Jankovic J, Stacy M, CNS Drugs 2007 21 677 692 10.2165/00023210-200721080-00005 17630819
2. The MPTP model of Parkinson's disease. Smeyne RJ, Jackson-Lewis V, Mol Brain Res 2005 134 57 66 10.1016/j.molbrainres.2004.09.017 15790530
3. Genetic and environmental factors in the cause of Parkinson's disease. Warner TT, Schapira AHV, Ann Neurol 2003 53 16 S25 10.1002/ana.10487 12666095
4. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, Obeso JA, Lancet Neurol 2009 8 1128 1139 10.1016/S1474-4422(09)70293-5 19909911
5. Missing pieces in the Parkinson's disease puzzle. Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AH, Halliday G, Nat Med 2010 16 653 661 10.1038/nm.2165 20495568
6. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Hirsch EC, Hunot S, Lancet Neurol 2009 8 382 397 10.1016/S1474-4422(09)70062-6 19296921
7. Neuroinflammation in Parkinson's disease. Lee J-K, Tran T, Tansey MG, J Neuroimmune Pharmacol 2009 4 419 429 10.1007/s11481-009-9176-0 19821032
8. Reactive microglia are positive for HLADR in the substantia nigra of Parkinson's and Alzheimer's disease brains. McGeer P, Itagaki S, Boyes B, McGeer E, Neurology 1988 38 1285 1285 10.1212/WNL.38.8.1285 3399080
9. Chronic microglial activation and progressive dopaminergic neurotoxicity. Block M, Hong J, Biochem Soc Trans 2007 35 1127 1132 10.1042/BST0351127 17956294
10. Neuroinflammation in Parkinson's disease. Hirsch EC, Vyas S, Hunot S, Parkinsonism Relat Disord 2012 18 210 S212 22166438
11. Oxidative stress in genetic mouse models of Parkinson's disease. Varçin M, Bentea E, Michotte Y, Sarre S, Oxid Med Cell Longev 2012 2010 624925 doi:10.1155/2012/624925
12. Antioxidants, oxidative stress, and degenerative neurological disorders. Floyd RA, Exp Biol Med 1999 222 236 245 10.1046/j.1525-1373.1999.d01-140.x
13. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS, J Neurosci 2000 20 6309 6316 10934283
14. Neuroinflammation of the nigrostriatal pathway during progressive 6OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Cicchetti F, Brownell A, Williams K, Chen Y, Livni E, Isacson O, Eur J Neurosci 2002 15 991 998 10.1046/j.1460-9568.2002.01938.x 11918659
15. Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T, Neurosci Lett 1994 165 208 210 10.1016/0304-3940(94)90746-3 8015728
16. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFα, and INFγ concentrations are elevated in patients with atypical and idiopathic parkinsonism. Brodacki B, Staszewski J, Toczyłowska B, Kozłowska E, Drela N, Chalimoniuk M, Stȩpien A, Neurosci Lett 2008 441 158 162 10.1016/j.neulet.2008.06.040 18582534
17. Hepatoprotective effect of silyamarin in individuals chronically exposed to hydrogen sulfide; modulating influence of TNF-α cytokine genetic polymorphism. Mandegary A, Saeedi A, Eftekhari A, Montazeri V, Sharif E, Daru 2013 21 28 10.1186/2008-2231-21-28 23566372
18. Silymarin suppresses TNF-induced activation of NF-κB, c-Jun N-terminal kinase, and apoptosis. Manna SK, Mukhopadhyay A, Van NT, Aggarwal BB, J Immunol 1999 163 6800 6809 10586080
19. Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Gupta O, Sing S, Bani S, Sharma N, Malhotra S, Gupta B, Banerjee S, Handa S, Phytomedicine 2000 7 21 24 10.1016/S0944-7113(00)80017-3 10782486
20. The correlation between NFκB inhibition and disease activity by coadministration of silibinin and ursodeoxycholic acid in experimental colitis. Esmaily H, VaziriBami A, Miroliaee AE, Baeeri M, Abdollahi M, Fundam Clin Pharmacol 2011 25 723 733 10.1111/j.1472-8206.2010.00893.x 21077947
21. Neuroprotective effect of silymarin in 6-hydroxydopamine hemi-parkinsonian rat: involvement of estrogen receptors and oxidative stress. Baluchnejadmojarad T, Roghani M, Mafakheri M, Neurosci Lett 2010 480 206 210 10.1016/j.neulet.2010.06.038 20600617
22. Effect of the bioflavonoid silymarin on the in vitro activity and expression of superoxide dismutase (SOD) enzyme. Muzes G, Deak G, Lang I, Nekam K, Gergely P, Feher J, Acta Physiol Hung 1991 78 3 9 1763650
23. Silymarin protects dopaminergic neurons against lipopolysaccharideinduced neurotoxicity by inhibiting microglia activation. Wang MJ, Lin WW, Chen HL, Chang YH, Ou HC, Kuo JS, Hong JS, Jeng KCG, Eur J Neurosci 2002 16 2103 2112 10.1046/j.1460-9568.2002.02290.x 12473078
24. Silymarin protects neurons from oxidative stress associated damages in focal cerebral ischemia: A behavioral, biochemical and immunohistological study in Wistar rats. Raza SS, Khan MM, Ashafaq M, Ahmad A, Khuwaja G, Khan A, Siddiqui MS, Safhi MM, Islam F, J Neurol Sci 2011 309 45 54 10.1016/j.jns.2011. 07.035 21840019
25. Preventive effect of silymarin in cerebral ischemia-reperfusion-induced brain injury in rats possibly through impairing NF-κB and STAT-1 activation. Hou Y-C, Liou K-T, Chern C-M, Wang Y-H, Liao J-F, Chang S, Chou Y-H, Shen Y-C, Phytomedicine 2010 17 963 973 10.1016/j.phymed.2010.03.012 20833521
26. Paxinos G, Watson C, The rat brain in stereotaxic coordinates UK: Academic press, Elsevier Inc. 2007
27. Lipid peroxidation at various estradiol concentrations in human circulation during ovarian stimulation with exogenous gonadotropins. Kaya H, Sezik M, Ozkaya O, Dittrich R, Siebzehnrubl E, Wildt L, Horm Metab Res 2004 36 693 695 10.1055/s-2004-826018 15523594
28. Pre-treatment with silymarin reduces brain myeloperoxidase activity and inflammatory cytokines in 6-OHDA hemi-parkinsonian rats. Haddadi R, Mohajjel Nayebi A, Brooshghalan SE, Neurosci Lett 2013 555 106 111 24045063
29. Silymarin effect on amyloid-β plaque accumulation and gene expression of APP in an Alzheimer's disease rat model. Yaghmaei P, Azarfar K, Dezfulian M, Ebrahim-Habibi A, Daru 2014 22 24 10.1186/2008-2231-22-24 24460990
30. Buspirone improves 6-hydroxydopamine-induced catalepsy through stimulation of nigral 5-HT (1A) receptors in rats. Nayebi AM, Rad SR, Saberian M, Azimzadeh S, Samini M, Pharmacol Rep 2010 62 258 264 20508280
31. Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits. Carvalho MM, Campos FL, Coimbra B, Pêgo JM, Rodrigues C, Lima R, Rodrigues AJ, Sousa N, Salgado AJ, Mol Neurodegene 2013 8 14 10.1186/1750-1326-8-14
32. Animal models of Parkinson's disease progression. Meredith GE, Sonsalla PK, Chesselet M-F, Acta Neuropathol 2008 115 385 398 10.1007/s00401-008-0350-x 18273623
33. 6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cδ Hanrott K, Gudmunsen L, O'Neill MJ, Wonnacott S, J Biol Chem 2006 281 5373 5382 16361258
34. Modeling neuroinflammatory pathogenesis of Parkinson's disease. Barnum CJ, Tansey MG, Prog Brain Res 2010 184 113 132 20887872
35. Protective effect of silymarin on oxidative stress in rat brain. Nencini C, Giorgi G, Micheli L, Phytomedicine 2007 14 129 135 10.1016/j.phymed.2006.02. 005 16638633
36. Neuroprotective effect of sulforaphane in 6-hydroxydopamine-lesioned mouse model of Parkinson's disease. Fabiana M, Andrea T, Giulia S, Cecilia B, Manuel ZMJ, Giorgio C-F, Patrizia H, Neurotoxicology 2013 36 63 71 23518299
37. Increase in level of tumor necrosis factor (TNF)-α in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic L-DOPA on the TNF-α induction. Mogi M, Togari A, Tanaka K, Ogawa N, Ichinose H, Nagatsu T, Neurosci Lett 1999 268 101 104 10.1016/S0304-3940(99)00388-2 10400088
38. Changes in cytokines and neurotrophins in Parkinson's disease. Nagatsu T, Mogi M, Ichinose H, Togari A, J Neural Transm Suppl 2000 36 277 290
39. Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T, Neurosci Lett 1994 180 147 150 10.1016/0304-3940(94)90508-8 7700568
40. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, Knapp DJ, Crews FT, Glia 2007 55 453 462 10.1002/glia.20467 17203472
41. Molecular mechanisms of pathogenesis of Parkinson's disease. Shadrina M, Slominsky P, Limborska S, Int Rev Cell Mol Biol 2010 281 229 266 20460187
42. Role of cytokines in inflammatory process in Parkinson's disease. Sawada M, Imamura K, Nagatsu T, J Neural Transm Suppl 2006 70 373 381 10.1007/978-3-211-45295-0-57 17017556